Claims for Patent: 9,085,627

Summary for Patent: 9,085,627

Title:	Expression system with SAR element from IFN.alpha.2
Abstract:	A short human genomic nucleotide sequence from the SAR3 region of the human interferon .alpha.2 gene permits enhances expression stability in the absence of drug selection and permits generation of stable clones or stable pools of cells for producing recombinant proteins. Although stable clones may be generated, the ability to generate stable pools reduces the burden of generating stable clones.
Inventor(s):	Durocher; Yves (Quebec, CA)
Assignee:	National Research Council of Canada (Ottawa, Ontario, unknown)
Application Number:	14/110,944
Patent Claims:	1. An isolated polynucleotide comprising the nucleotide sequence as set forth in SEQ ID NO: 1. 2. An expression system for producing recombinant protein in a host cell comprising, operably linked: a gene for encoding a protein of interest; nucleotide sequences for operation of the expression system; and, an expression enhancer incorporated in cis in the expression system for enhancing expression of the gene, the expression enhancer being the polynucleotide of claim 1. 3. The expression system according to claim 2 being a plasmid vector. 4. The expression system according to claim 2 being an episomal vector. 5. The expression system according to claim 2, wherein the gene encodes a monoclonal antibody, an erythropoietin, an interferon, a vascular endothelial growth factor, a stem cell growth factor, a growth hormone or an insulin-like growth factor binding protein. 6. The expression system according to claim 2, wherein the nucleotide sequences for operation of the expression system comprise one or more of a promoter, an origin of replication, a leader, a splice donor, an intron, a splice accepter, a selectable marker, a cloning site, a restriction enzyme consensus site and a polyadenylation signal. 7. An isolated host cell comprising the expression system of claim 2. 8. The isolated host cell according to claim 7 which is a mammalian cell. 9. The host cell according to claim 8, wherein the mammalian cell is a Human Embryonic Kidney 293 (HEK293) cell, a Chinese Hamster Ovary (CHO) cell, a Baby Hamster Kidney (BHK21) cell, a PerC6 cell or a COS7 cell. 10. The host cell according to claim 8, wherein the mammalian cell is a Human Embryonic Kidney 293 (HEK293) cell or a Chinese Hamster Ovary (CHO) cell. 11. A method of producing a recombinant protein of interest comprising: transfecting a host cell with the expression system of claim 2; growing the host cell; expressing the gene to produce the protein of interest; and, recovering the protein of interest. 12. The method according to claim 11, wherein the host cell is a mammalian cell. 13. The method according to claim 11, wherein the host cell is a Human Embryonic Kidney 293 (HEK293) cell, a Chinese Hamster Ovary (CHO) cell, a Baby Hamster Kidney (BHK21) cell, a PerC6 cell or a COS7 cell. 14. The method according to claim 11, wherein the host cell is a Human Embryonic Kidney 293 (HEK293) cell or a Chinese Hamster Ovary (CHO) cell.

Details for Patent 9,085,627

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2031-04-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2031-04-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2031-04-13